FDA approves Agios' IDH1 inhibitor Tibsovo for AML

FDA approved Tibsovo ivosidenib (formerly AG-120) from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to treat relapsed or refractory acute myelogenous leukemia (AML) in

Read the full 213 word article

User Sign In